The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...

The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...

The “Dumb Blonde” podcast host said she is scared of taking a higher dose of tirzepatide because she’s “scared” of side ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...

Americans who turned to telehealth companies and compounding pharmacies for cheap versions of Eli Lilly & Co.’s weight-loss ...